Use of Quetiapine as a Coadjuvant to Benzodiazepines in General Anxiety Disorder in Patients Aged Over 20 Years at Hospital Naval Guayaquil


Generalized anxiety disorder is the most prevalent mental disorder worldwide. The use of quetiapine + benzodiazepines has been shown to reduce symptoms in patients with generalized anxiety disorder who do not respond adequately to the exclusive use of benzodiazepines. Despite the benefits shown in Ecuador, there are no published studies about its effectiveness. This is a prevalent, retrospective, cross-sectional, descriptive, and analytical study carried out at the Hospital Naval de Guayaquil, in patients aged over 20 years diagnosed with generalized anxiety disorder and had undergone treatment with quetiapine, benzodiazepines, or both during the years 2017–2020. The average age of diagnosis of generalized anxiety disorder is 45.12 years. It prevails in married male patients diagnosed at 39.95 years. Benzodiazepine is the drug that produces clinical improvement in 38% of patients. However, it does not present great variation before quetiapine + benzodiazepine, which produced an improvement in 27% of patients. The treatment time according to the type of drug used is shorter with quetiapine, lasting 4.32 months. However, the Kruskal-Wallis test established that the treatment time is shorter using the combination of quetiapine as a coadjuvant to benzodiazepine with a significance of >0.05. The improvement of the sleep disorder stood out with the use of benzodiazepine in 38.57%. The benzodiazepine produces clinical improvement in 38% and in turn improves the sleep disorder in 38.57%. The use of quetiapine as a coadjuvant to benzodiazepines decreases the treatment time.

Keywords: Ecuador, anxiety disorder, benzodiazepines, quetiapine.


El trastorno de ansiedad generalizada es el desorden mental más prevalente a nivel mundial. El uso de quetiapina + benzodiacepinas, ha demostrado disminuir la sintomatología en pacientes sin mejoría con el uso exclusivo de benzodiacepinas. Sin embargo, pese al beneficio demostrado en Ecuador, no existen estudios publicados sobre su efectividad. Materiales y métodos. Estudio de prevalencia, retrospectivo, transversal, descriptivo y analítico realizado en el Hospital Naval de Guayaquil, en pacientes mayores de 20 años que acudieron con diagnóstico de trastorno de ansiedad generalizada y que fueron sometidos a tratamiento con quetiapina , benzodiacepinas o ambas durante los años 2017-2020. Resultados. El trastorno de ansiedad generalizada se diagnostica a la edad promedio 45,12 años. Prevalece en los pacientes casados de sexo masculino diagnosticados a los 39,95 años. La benzodiacepina es el fármaco que produce mejoría clínica en un 38% de los pacientes. Sin embargo, no presenta gran variación ante la quetiapina + benzodiacepina que produjo la mejoría de 27% de los pacientes. El tiempo de tratamiento de acuerdo al tipo de fármaco utilizado es menor con quetiapina durando 4,32 meses. Sin embargo, el test de Kruskal-Wallis estableció que el tiempo de tratamiento es menor utilizando la combinacion de quetiapina mas benzodiacepina con una significacia menor que 0.05. La mejoría del trastorno del sueño destacó con el uso de benzodiacepina en 38,57%. Conclusión. La benzodiacepina produce mejoría clínica en un 38%, mejorando además el trastorno del sueño en un 38,57%. El uso de quetiapina más benzodiacepina disminye el tiempo de tratamiento.

Palabras Clave: Ecuador,trastorno de ansiedad, benzodiacepinas, quetiapina.

[1] Patriquin MA, Mathew SJ. The neurobiological mechanisms of generalized anxiety disorder and chronic stress. Chronic Stress (Thousand Oaks). 2017;1:1–10.

[2] Muskin P. What are anxiety disorders? American Psychiatric Association. [Internet] 2021 [cited 31 March 2022]. Available from: anxiety-disorders/what-are-anxiety-disorders

[3] Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues in Clinical Neuroscience. [Internet]. 2015 [cited 30 March 2022];17(3):327- 335. Available from:

[4] Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depression and Anxiety. [Internet]. 2002 [cited 30 March 2022];16(4):162- 171. Available from:

[5] López Vantour A, Aroche Arzuaga A, Bestard Romero J, Ocaña Fontela N. Uso y abuso de las benzodiazepinas. MEDISAN. [Internet]. 2010 [cited 30 March 2022];14(4):555-565. Available from: sci_abstract&pid=S102930192010000400017&lng=es&nrm=iso&tlng=es

[6] Griffin CE, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system–mediated effects. Ochsner Journal. [Internet] 2013 [cited 30 March 2022];13(2):214-223. Available from:

[7] Ayuso Gutiérrez JL. ¿Está justificado el tratamiento prolongado con benzodiacepinas? Salud Mental. [Internet] 2008; [cited 30 March 2022] 31(6):429-430. Available from: 33252008000600001&lng=es&nrm=iso&tlng=es

[8] Sadock B, Ruiz P, Sadock V (Unidos E, editor). Manual Psiquiatría Clínica. 4.a. Wolters Kluwer; 2018. pp. 106–111.

[9] Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. Dialogues in Clinical Neuroscience. [Internet]. 2017 [cited 31 March 2022];19(2):93- 107. Available from:

[10] Hershenberg R, Gros DF, Brawman-Mintzer O. Role of atypical antipsychotics in the treatment of generalized anxiety disorder. CNS Drugs. [Internet] 2014 [cited 30 March 2022]; 28(6):519-533.Available from:

[11] Maneeton N, Maneeton B, Woottiluk P, Likhitsathian S, Suttajit S, Boonyanaruthee V, et al. Quetiapine monotherapy in acute treatment of generalized anxiety disorder: A systematic review and meta-analysis of randomized controlled trials. Drug Design, Development and Therapy. 2016 Jan;10:259–276.

[12] Locke AB, Kirst N, Shultz CG. Diagnosis and management of generalized anxiety disorder and panic disorder in adults. American Family Physician. 2015 May;91(9):617–624.

[13] Reyes Marrero R, de Portugal Fernández del Rivero E. Trastornos de ansiedad. Med - Programa Form Médica Contin Acreditado. 2019;12(84):4911-4917.

[14] Gören JL, Wiseman CN. Is quetiapine effective for anxiety? Current Psychiatry Reports. 2012;11(8):1–2.

[15] World Health Organization. Depression and other common mental disorders: global health estimates. World Health Organization [Internet]. 2017. [cited 31 March 2022].1- 20. Available from:

[16] Fisher K, Seidler ZE, King K, Oliffe JL, Robertson S, Rice SM. Men’s anxiety, why it matters, and what is needed to limit its risk for male suicide. Discover Psychology. 2022;2(1):18.

[17] Lijster JM, Dierckx B, Utens EM, Verhulst FC, Zieldorff C, Dieleman GC, et al. The age of onset of anxiety disorders. The Canadian Journal of Psychiatry. 2017 Apr;62(4):237–246.

[18] Bastida-González R, Valdez-Medina JL, Valor-Segura I, Fuentes NI, Rivera-Aragón S. Satisfacción marital y estado civil como factores protectores de la depresión y ansiedad. Revista Argentina de Clinica Psicologica. 2017;36:95–102.

[19] Huh J, Goebert D, Takeshita J, Lu BY, Kang M. Treatment of generalized anxiety disorder: a comprehensive review of the literature for psychopharmacologic alternatives to newer antidepressants and benzodiazepines. Primary Care Companion for CNS Disorders. 2011;13(2):2.

[20] Garakani A, Murrough JW, Freire RC, Thom RP, Larkin K, Buono FD, et al. Pharmacotherapy of anxiety disorders: Current and emerging treatment options. Frontiers in Psychiatry. 2020 Dec;11:595584.